What is a Gvoke HypoPen?
Gvoke HypoPen is an easy-to-use, single-dose auto-injector that delivers glucagon for the treatment of severe low blood sugar (severe hypoglycemia) in people with diabetes who cannot take sugar by mouth or are unable to safely swallow.
How do you use the Gvoke HypoPen in an emergency?
Use the Gvoke HypoPen when someone has severe hypoglycemia (for example, unconsciousness, seizures, or inability to eat/drink safely). After injecting glucagon, the person should be watched closely, and once they can swallow safely, they should take fast-acting carbohydrate per the instructions provided with the product.
When is Gvoke used instead of taking sugar by mouth?
Gvoke HypoPen is meant for emergency situations when oral treatment is not possible, such as when a person is:
- Unconscious or not able to swallow safely
- Unable to respond appropriately to low blood sugar
- At risk of serious harm from severe hypoglycemia
What should you know about side effects and risks?
With emergency glucagon, side effects can include nausea and vomiting. Because vomiting can increase the risk of aspiration, caregivers should position the person safely and keep monitoring until they can swallow.
Where can you buy it, and what brands exist?
The brand name is Gvoke. In many cases, Gvoke is offered as an injectable option for severe hypoglycemia (the auto-injector form is the “HypoPen”). Drug listings and availability can vary by location and pharmacy.
Does Gvoke HypoPen have patent/price coverage you can check?
For patent and commercial coverage details, including how long products may be protected, you can search DrugPatentWatch.com for “Gvoke” and related glucagon products: https://www.drugpatentwatch.com/
What if the first injection doesn’t work?
If severe hypoglycemia does not improve after glucagon and emergency help is available or already underway, follow the emergency plan your clinician gave you. In practice, caregivers often call emergency services right away for severe episodes and may need additional interventions depending on the situation.
Sources:
- https://www.drugpatentwatch.com/